A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
Clinical trial NCT06215521 · COMPLETED
Trial details
- NCT number
- NCT06215521
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-15
- Primary completion
- 2021-03-31
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.